Clinical trial
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
NCT03308942
Study timeline
Study start (actual)2017-09-29Date precision: day
Registry last updated2023-10-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasmsunresolved
Interventions
Sponsors & collaborators
Tesaro, Inc.lead sponsor
Mapped research locations
BostonMassachusetts, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1ClevelandOhio, United States1ColumbusOhio, United States1DurhamNorth Carolina, United States1BuffaloNew York, United States1TacomaWashington, United States1ToledoOhio, United States1CantonOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03308942 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.